分享到:

Shire收购瑞典生物技术公司Premacure

2013-4-1 13:22:00
核心提示: Shire已收购了瑞典生物技术公司Premacure。该公司正在开发一种蛋白替代疗法,预防早产儿的视网膜病变。收购可以加强Shire的罕见病业务,并将产品线扩大至新生儿产品。(生物谷Bioon.com) 英文报道: UPDATE 1-Shire boosts rare diseases business by buying Premacure * Gets Phase II drug for...

Shire已收购了瑞典生物技术公司Premacure。该公司正在开发一种蛋白替代疗法,预防早产儿的视网膜病变。收购可以加强Shire的罕见病业务,并将产品线扩大至新生儿产品。(生物谷Bioon.com)

英文报道:

UPDATE 1-Shire boosts rare diseases business by buying Premacure

* Gets Phase II drug for eye disorder in premature babies

* Financial terms of Swedish acquisition not disclosed

(Reuters) - Shire increased its investment in rare diseases on Tuesday by acquiring privately held Swedish biotech firm Premacure, which is developing a drug for a potentially blinding eye disorder in premature babies.

Britain''s third biggest drugmaker did not reveal how much it was paying for the Uppsala-based business but said it would pay a sum upfront followed by contingent payments based on clinical development and commercial success.

The acquisition takes Shire into the new area of neonatology - the treatment of sick or premature newborn infants - and expands its already substantial presence in rare diseases.

Treating diseases that affect only a small number of patients is a growing focus for many drug companies given the high prices that can be achieved.

Premacure, which was launched in 2006, has an experimental protein replacement medicine in mid-stage Phase II clinical development for the prevention of retinopathy of prematurity (ROP).

Normal full-term babies produce enough growth factors on their own to prevent diseases like ROP. But those born before 31 weeks may lack chemicals such as insulin-like growth factor 1 (IGF-1), which can result in life-long complications like ROP.

Shire said its human genetic therapies unit would continue with the Phase II study, the primary goal of which is to restore the IGF-1 levels in premature infants to those found in babies born at full term.
 

分享到:
相关文章
ADVERTISEMENT
订阅电子报
点击下面电子报名称可以预览样本